Short-term neoadjuvant androgen deprivation therapy and external-beam radiotherapy for locally advanced prostate cancer: Long-term results of RTOG 8610

Journal of Clinical Oncology

Volumn 26, Issue 4, 2008, Pages 585-591

  Roach III, Mack ^a   Bae, Kyounghwa ^b   Speight, Joycelyn ^b   Wolkov, Harvey B ^b   Rubin, Phillip ^b   Lee, R Jeffrey ^b   Lawton, Colleen ^b   Valicenti, Richard ^b   Grignon, David ^b   Pilepich, Miljenko V ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; FLUTAMIDE; GOSERELIN; ANTIANDROGEN;

ADULT; AGED; ARTICLE; BIOCHEMISTRY; CANCER MORTALITY; CANCER STAGING; CANCER SURVIVAL; CARDIOVASCULAR RISK; CLINICAL TRIAL; DISTANT METASTASIS; EXTERNAL BEAM RADIOTHERAPY; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; PROSTATE CANCER; SURVIVAL TIME; TREATMENT OUTCOME; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; LYMPH NODE METASTASIS; MIDDLE AGED; MORTALITY; MULTIMODALITY CANCER THERAPY; PROSTATE TUMOR; RANDOMIZED CONTROLLED TRIAL; SURVIVAL RATE;

AGED; AGED, 80 AND OVER; ANDROGEN ANTAGONISTS; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; FLUTAMIDE; FOLLOW-UP STUDIES; GOSERELIN; HUMANS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROSTATIC NEOPLASMS; SURVIVAL RATE;

EID: 39149085396     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2007.13.9881     Document Type: Article

References (30)

1. Pilepich MV, Caplan R, Byhardt RW, et al: Phase III trial of androgen suppression using goserelin in unfavorable-prognosis carcinoma of the prostate treated with definitive radiotherapy: Report of Radiation Therapy Oncology Group Protocol 8531. J Clin Oncol 15:1013-1021, 1997
2. Bolla M, Collette L, Blank L, et al: Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomized trial. Lancet 360:103-106, 2002
3. Hanks GE, Pajak TF, Porter A, et al: Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: The Radiation Therapy Oncology Group Protocol 9202. J Clin Oncol 21:3972-3978, 2003
4. Granfors T, Modig H, Damber JE, et al: Combined orchiectomy and external radiotherapy versus radiotherapy alone for nonmetastatic prostate cancer with or without pelvic lymph node involvement: A prospective randomized study. J Urol 159:2030-2034, 1998
5. Shahinian VB, Kuo YF, Freeman JL, et al: Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med 352:154-164, 2005
6. Braga-Basaria M, Dobs AS, Muller DC, et al: Metabolic syndrome in men with prostate cancer undergoing long-term androgen-deprivation therapy. J Clin Oncol 24:3979-3983, 2006
7. D'Amico AV, Manola J, Loffredo M, et al: 6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: A randomized controlled trial. JAMA 292:821-827, 2004
8. Denham JW, Steigler A, Lamb DS, et al: Short-term androgen deprivation and 13 radiotherapy for locally advanced prostate cancer: Results from the Trans-Tasman Radiation Oncology Group 96.01 randomized controlled trial. Lancet Oncol 6:841-850, 2005
9. Pilepich MV, Winter K, John MJ, et al: Phase III radiation therapy oncology group (RTOG) trial 8610 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate. Int J Radiat Oncol Biol Phys 50:1243-1252, 2001
10. Roach M III, Hanks G, Thames H, Jr., et al: Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: Recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys 65:965-974, 2006
11. Kaplan EL, Meier P: Nonparameteric estimation from incomplete observations. Journal American Statistical Association 53:457-481, 1958
12. Mantel N: Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 50:163-170, 1966
13. Kim K, Tsiatis AA: Study duration for clinical trials with survival response and early stopping rule. Biometrics 46:81-92, 1990
14. Gray R: A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat 16:1141-1154, 1988
15. Fine J GR: A proportional hazards model for the subdistribution of a competing risk. J Am Statist Assoc 94:496-509, 1999
16. Zelefsky MJ, Harrison A: Neoadjuvant androgen ablation prior to radiotherapy for prostate cancer: Reducing the potential morbidity of therapy. Urology 49:38-45, 1997
17. Zietman AL: The case for neoadjuvant androgen suppression before radiation therapy. Mol Urol 4:203-208, 2000; discussion 215
18. Van Poppel H, Ridder DD, Elgamal AA, et al: Neoadjuvant hormonal therapy before radical prostatectomy decreases the number of positive surgical margins in stage T2 prostate cancer: Interim results of a prospective randomized trial. J Urol 154:429-434, 1995
19. Meng MV, Grossfeld GD, Carroll PR, et al: Neoadjuvant strategies for prostate cancer prior to radical prostatectomy. Semin Urol Oncol 20:10-18, 2002 (3 suppl 1)
20. Gleave ME, Goldenberg SL, Chin JL, et al: Randomized comparative study of 3 versus 8-month neoadjuvant hormonal therapy before radical prostatectomy: Biochemical and pathological effects. J Urol 166:500-506, 2001; discussion 506-507
21. Roach M, Valicenti R, Asbell SO, Lawton C, Thomas CR, Shipley W.U.: Whole Pelvic, "Mini-Pelvic" or Prostate Only External Beam Radiotherapy Field following Neoadjuvant and Concurrent Hormonal Therapy: In Patients Treated on RTOG 9413. Int J Rad Bio Phys 66:647-653, 2006
22. Saad F, Gleason DM, Murray R, et al: A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 94:1458-1468, 2002
23. Petrylak DP, Tangen CM, Hussain MH, et al: Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 351:1513-1520, 2004
24. Pickles T, Agranovich A, Berthelet E, et al: Testosterone recovery following prolonged adjuvant androgen ablation for prostate carcinoma. Cancer 94:362-367, 2002
25. D'Amico AV, Denham JW, Crook J, et al: Influence of androgen suppression therapy for prostate cancer on the frequency and timing of fatal myocardial infarctions. J Clin Oncol 25:2420-2425, 2007
26. Roach M III: Regarding the influence of adjuvant suppression therapy for prostate cancer on the frequency and timing of fatal myocardial infarction: How real is the risk? J Clin Oncol 25:5325-5326, 2007
27. Penson DF, Albertsen PC, Nelson PS, et al: Determining cause of death in prostate cancer: Are death certificates valid? J Natl Cancer Inst 93:1822-1823, 2001
28. Pollack A, Zagars GK, Starkschall G, et al: Prostate cancer radiation dose response: Results of the M.D. Anderson phase III randomized trial Int J Radiat Oncol Biol Phys 53:1097-1105, 2002
29. Zietman AL, DeSilvio M, Slater JD, Rossi CJ, Yonemoto LT, Slater JM, Berkey B, Adams JA, Shipley WU: A randomized trial comparing conventional dose (70.2gye) and high-dose (79.2gye) conformal radiation in early stage adenocarcinoma of the prostate: Results of an interim analysis of PROG 9509, in Cox (ed): Proceedings of American Society for Therapeutic Radiology and Oncology. Atlanta, GA, Elsevier, 2004, pp S131-132
30. Peeters ST, Heemsbergen WD, Koper PC, et al: Dose-response in radiotherapy for localized prostate cancer: Results of the Dutch multicenter randomized phase III trial comparing 68 Gy of radiotherapy with 78 Gy. J Clin Oncol 24:1990-1996, 2006